


Instrumenting the Health Care Enterprise for Discovery in the Course of Clinical Care


Shawn Murphy MD, Ph.D. Chief Research Information Officer Harvard Medical School / Mass General Brigham

Personalized Medicine and Genomic technology are critical to managing populations



- Managing a population involves improving health outcomes of the group as a whole by identifying, monitoring and addressing health needs of individuals through:
 - Subpopulation stratification
 - Targeted, evidence-based treatment protocols
 - Predictive analytics

Example: PPARy Pro12Ala and Diabetes



High Throughput Methods for supporting Translational Research

- Set of patients is selected from medical record data in a high throughput fashion
- Investigators explore phenotypes of these patients using Machine Learning tools and a translational team developed to work specifically with medical record data
- Distributed networks cross institutional boundaries for phenotype selection, public health, and hypothesis testing
- Digital medicine is delivered into clinical care through Digital Twin

Data problems that make working with Electronic Healthcare Data to conduct research difficult


- 1) There are significant risks of a data breach which will result in very large fines and loss of confidence in the hospitals where the breach occurred.
- 2) The data are not collected for research purposes, and therefore the data can be poorly structured with significant omissions, biases, and inaccuracies.

Research Patient Data Registry (RPDR) at Mass General Brigham to find patient cohorts and distribute data

Query construction in web tool


1) Queries for aggregate patient numbers

- Warehouse of in & outpatient clinical data
- 6.7 million Mass General Brigham patients
- 2.6 billion diagnoses, medications, genomics, procedures, laboratories, & physical findings coupled to demographic & visit data
- Authorized use by faculty status
- Clinicians can construct complex queries
- Queries cannot identify individuals, internally can produce identifiers for (2)



2) Returns detailed patient data

- Start with list of specific patients, usually from (1)
- Authorized use by IRB Protocol
- Returns contact and PCP information, demographics, providers, visits, diagnoses, medications, procedures, laboratories, microbiology, reports (discharge, LMR, operative, radiology, pathology, cardiology, pulmonary, endoscopy), and images into a Microsoft Access database and text files.




Results - broken down by number distinct of patients


Participation of the second	prer provided by Partners HealthCare System	_ 7 🗙
<u>File E</u> dit <u>V</u> iew F <u>a</u> vorites <u>T</u> ools <u>H</u> elp		.
🚱 Back 🔹 🐑 💌 😰 🏠 🔎 Search 👷 Fa	avorites 🚱 🛜 🍡 🎇 🛄 🎇	
Address ahttp://rpdrweb/rpdrwebclient/querytool.aspx?res=768		~
RPDR Enhanced Query Tool	Logging: Duey, Stacey A. in workgroup of Shawn Murphy, MD	
Find Patients Match Controls Analyze Patients Rec	quest Detailed Data Request Specimens Understand Data Get Help	
Query Items Find Terms Previous Queries	Query Name: Jsut Diagnos AMI	
Standard Query Items Encounter detail Demographics detail Diagnosis Circulatory system Acute Rheumatic fever Acute Rheumatic fever Cardiac problem-Oncall Cardiac risk factors-Oncall Cardiac risk stratification-Oncall Cardiac risk stratification Chronic Rheumatic heart disease Condition appetoris Standard Query Conditions in the perinatal period Congenital anomalies	GROUPS DO NOT HAVE TO OCCUR IN THE SAME VISIT Sensitivity<	ns' and
⊡ Congenital anomalies ⊡ Digestive system	Click the image or check box to request an aggregated count by	
Endocrine disorders Events of pregnancy	patient gender for this query.	
	Female Male 40 80 A B H W O U Alive Dec	ceased
AspTreeView/MetaDataTree_Sub_aspx2ParentEolderId=DGNCircula	tory system (390-459)0x5CTschemic heart disease (410-414)	Inet

AspTreeView/MetaDataTree_Sub.aspx?ParentFolderId=DGNCirculatory system (390-459)0x5CIschemic heart disease (410-414)

🧐 Local intranet



Theory of Kimball translated to Healthcare Data



🚰 RPDR Detailed Data Request Wizard Web Page I	Dialog
RPDR [DETAILED DATA REQUEST WIZARD
	d in the RPDR Identified database) to obtain data from the RPDR
You are logged in a	is Murphy, Shawn N. in workgroup Shawn Murphy, MD
	Select protocol number(s)
Partners IRB (required):	mgh-demo-1
	Title: RPDR protocol - Demonstration IRB number for Dr. Murphy Status: Active
Newton Wellesley Hospital IRB:	NWH Demo 1
	Title: test
	Status: Active
Spaulding Rehabilitation Hospital IRB:	
Options for returned set of patien	ts:
Create a static set of patient	nts from this query that can be used in other RPDR queries
Rerun the base query sho	wh above to obtain a fresh set of patients
Help <	Back STEP 3 Next > Cancel

🚰 RPDR Detailed Data Request Wizard Web Page Dialog	×
RPDR DETAILED DATA REQUEST WIZARD Using IRB#mgh-demo-1 (found in the RPDR Identified database) to obtain data from the RPDR You are logged in as Murphy, Shawn N. in workgroup Shawn Murphy, MD	
Please select if you would like a HIPAA-defined (deidentified) limited data set or an identified data set	
VVhat's a limited data set?	
 C Limited Data Set The files that result from this request will be available in a protected file share with no special encryption. Identified Data Set The text files that result from this request will be encrypted and the Microsoft Access file will be password State of the state of the microsoft Access file will be password The text files that result from this request will be encrypted and the Microsoft Access file will be password The text files that result from this request file will be password The text files that result from this request file will be password The text files that result form the microsoft for the password The text files that result form the microsoft for the password The text files that result form the microsoft for the password The text files that result form the microsoft for the password The text files that result form the microsoft for the password The text files that result form the microsoft for the password The text files that result form the microsoft for the password	
protected. In <u>order to access the data, a password will</u> be provided.	
Help < Back STEP 8 Next > Cancel	

_

🚰 RPDR Detailed Data Request Wizard Web Page Dialog	×
RPDR DETAILED DATA REQUEST WIZARD Using IRB#mgh-demo-1 (found in the RPDR Identified database) to obtain data from the RPDR You are logged in as Murphy, Shawn N. in workgroup Shawn Murphy, MD	
Select the types of data that should be returned from the RPDR Only data allowed by your protocol should be chosen (Identified data sets will always return a set of identified patient medical numbers)	
 Detail Data Items Demographic Data Identifying Patient Information - not available for Limited Data Sets LMR (Longitudinal Medical Record) Medications, Diagnoses and Procedures Medications, Diagnoses and Procedures from Billing Data - only visits where query criteria occur all in the same visit Patient Clinical Reports - not available for Limited Data Sets Cardiology Reports Cardiology Data Microbiology Data Operative Notes Pathology Reports Radiology Reports Radiology Reports Transfusion Data, Blood Bank Data 	
Help < Back STEP 9 Next > Cancel	

Detailed data is gathered for request and distributed

- 🗆 ×

🚮 Process IRB files				
Environment Record O	ptions Help			
File: SNM0_022	502164303648842.XML			•
File Type: Control File	▼ Curre	ent Production Database:		 RPDR_12_5241
Update Statu	s 🔽 🦳 Start Process A	fter 🔽 9:00:00 PM 🔒	-	
IRB Information IRB Number: 200	2000000		ProcesIRB	Files: 🔲
Date from: 01/0		Ends: /1900	Process Co	ountDown:
Primary User; snm)		Status Det	ail
Files to MGH Users: Part	ners\snm0,Partners\zzp,Partners	s\kcs3	Contact.	/lab:□
BWH Users: Part	ners\kra1,Partners\snm0,Partne	rs\kcs3		
- Data Requested			Demograp	hics: 🔲
	Medical Record Numbers 👿	Chemistry	Encou	inter:
Encounters 🗖	Contact Information 🔲	Radiology		
Hematology 🗖	PCP 🗖	Pathology	/ 🗖 🔰 🕨	(BN: 🔲
Discharge Summaries 💌	Immunology 🗖	LMR Notes		ions: 🗍
Medications 🔽	Operative Notes 🗖	LMR Problems		ions.
LMR Allergies 🗖	LMR Medications 🗖	Build Access Database	Acces	s DB: 🔲
Groups: BUN				
		Run Close	e Cle	ar

Data is gathered from RPDR and other MGB sources


Output files placed in special directory

Image: Constraint of the sec in	٩,	Microsoft Access	- [MGH_Labs : Tab	le]				
Test Id Test Description Result Result Test Abmornal Flag Reference Unit Reference Range SQ-PTT Apperstat APTT 228 sec 22.1-35.1 SQ-PTT APTT 37.8 H sec 22.1-35.1 SQ-PTT APTT 37.8 H sec 22.1-35.1 SQ-PTT APTT 45.4 H sec 22.1-35.1 SQ-PTT APTT 45.1 MODERATELY H sec 22.1-35.1 SQ-PTT APTT 25.7 sec 22.1-35.1 Sec 22.1-35.1 SQ-PTT APTT 25.4 sec 22.1-35.1 Sec 22.1-35.1 SQ-PTT APTT 24.0 sec 22.1-35.1 Sec 22.1-35.1 SQ-PTT APTT 24.0 sec 22.1-35.1 Sec 22.1-35.1 SQ-PTT APTT 34.5 sec 22.1-35.1 Sec 22.1-35.1 SQ-PTT APTT 34.5 sec 22.1-35.1 Sec		Eile Edit View	Insert Format Recor	ds <u>T</u> ools <u>W</u> indow	Help			_ 8 ×
SQ-XPTT Superstat APTT 29.8 sec 22.1-36.1 SQ-PTT APTT 32.8 sec 22.1-36.1 SQ-PTT APTT 32.8 sec 22.1-36.1 SQ-PTT APTT 37.8 H sec 22.1-36.1 SQ-PTT APTT 46.4 H sec 22.1-36.1 SQ-PTT APTT 46.4 H sec 22.1-36.1 SQ-PTT APTT 25.7 sec 22.1-36.1 SQ-PTT APTT 25.4 sec 22.1-36.1 SQ-PTT APTT 24.4 sec 22.1-36.1 SQ-PTT APTT 24.7 sec 22.1-36.1 SQ-PTT APTT 24.7 sec 22.1-36.1 SQ-PTT APTT 24.7 sec 22.1-36.1 SQ-PTT APTT 34.5 sec 22.1-36.1 SQ-PTT APTT 40.0 H sec 22.1-36.1 SQ-PTT APTT		L - 日 🖨 🖸	x 🖤 🕺 🗈 🖻 :	🖋 🗠 🍭 🦉	<u>2</u> ↓ <u>₹</u> ↓ [™] [™]	T 7 🏘 🕨	💉 🛅 ⁄a - 🖸)
SQ-PTT APTT 32.8 sec 22.1-36.1 SQ-PTT APTT 37.8 H sec 22.1-36.1 SQ-PTT APTT 37.8 H sec 22.1-36.1 SQ-PTT APTT 46.4 H sec 22.1-36.1 SQ-PTT APTT 43.1 MODERATELY H sec 22.1-36.1 SQ-PTT APTT 25.7 sec 22.1-36.1 sec 22.1-36.1 SQ-PTT APTT 25.4 sec 22.1-36.1 sec 22.1-36.1 SQ-PTT APTT 24.7 sec 22.1-36.1 sec 22.1-36.1 SQ-PTT APTT 24.0 sec 22.1-36.1 sec 22.1-36.1 SQ-PTT APTT 24.7 sec 22.1-36.1 sec 22.1-36.1 SQ-PTT APTT 44.5 sec 22.1-36.1 sec 22.1-36.1 SQ-PTT APTT 40.0 H sec 22.1-36.1 sec	Ē	Test Id	Test Description	Result	-			Reference Range 🖻
SO-PTT APTT 37.8 H sec 22.1.35.1 SO-PTT APTT 46.4 H sec 22.1.35.1 SO-PTT APTT 43.1 MODERATELY H sec 22.1.35.1 SO-PTT APTT 25.7 sec 22.1.35.1 sec 22.1.35.1 SO-PTT APTT 25.7 sec 22.1.35.1 sec 22.1.35.1 SO-PTT APTT 23.7 sec 22.1.35.1 sec 22.1.35.1 SO-PTT APTT 24.7 sec 22.1.35.1 sec 22.1.35.1 SO-PTT APTT 24.0 sec 22.1.35.1 sec 22.1.35.1 SO-PTT APTT 34.5 sec 22.1.35.1 sec 22.1.35.1 SO-PTT APTT 40.0 H sec 22.1.35.1 sec 22.1.35.1 SO-PTT APTT 45.0 H sec 22.1.35.1 sec 22.1.35.1 sec 22.1.35.1 se		SQ-XPTT	Superstat APTT	29.8			sec	22.1-35.1
SQ-PTT APTT 46.4 H sec 22.1.36.1 SQ-PTT APTT 43.1 MODERATELY H sec 22.1.36.1 SQ-PTT APTT 25.7 sec 22.1.36.1 sec 22.1.36.1 SQ-PTT APTT 25.7 sec 22.1.36.1 sec 22.1.36.1 SQ-PTT APTT 23.7 sec 22.1.36.1 sec 22.1.36.1 SQ-PTT APTT 24.7 sec 22.1.36.1 sec 22.1.36.1 SQ-PTT APTT 44.7 sec 22.1.36.1 sec 22.1.36.1 SQ-PTT APTT 45.0 H sec 22.1.36.1 sec SQ-PTT APTT 33		SQ-PTT	APTT	32.8			sec	22.1-35.1
SQ-PTT APTT 43.1 MODERATELY H sec 22.1-36.1 SQ-PTT APTT 25.7 sec 22.1-36.1 sec 22.1-36.1 SQ-PTT APTT 23.7 sec 22.1-36.1 sec 22.1-36.1 SQ-PTT APTT 25.4 sec 22.1-36.1 sec 22.1-36.1 SQ-PTT APTT 24.7 sec 22.1-36.1 sec 22.1-36.1 SQ-PTT APTT 24.0 sec 22.1-36.1 sec 22.1-36.1 SQ-PTT APTT 24.7 sec 22.1-36.1 sec 22.1-36.1 SQ-PTT APTT 34.5 sec 22.1-36.1 sec 22.1-36.1 SQ-PTT APTT 45.0 H sec 22.1-36.1 sec 22.1-36.1 SQ-PTT APTT 45.0 H sec 22.1-36.1 sec 22.1-36.1 SQ-PTT APTT 37.9 H sec 22.1-36.1 sec		SQ-PTT	APTT	37.8		н	sec	22.1-35.1
SQ-PTT APTT 25.7 sec 22.1-36.1 SQ-PTT APTT 23.7 sec 22.1-36.1 SQ-PTT APTT 25.4 sec 22.1-35.1 SQ-PTT APTT 24.7 sec 22.1-36.1 SQ-PTT APTT 44.7 sec 22.1-36.1 SQ-PTT APTT 45.6 sec 22.1-36.1 SQ-PTT APTT 45.0 H sec 22.1-36.1 SQ-PTT Superstat APTT 33.6 *** Note: New n H sec 22.1-36.1 SQ-PTT APTT 34.3 sec 22.1-36.1 Sec SQ-PTT APTT 37.9 H sec 22.1-36.1 SQ-PTT		SQ-PTT	APTT	46.4		н	sec	22.1-35.1
SQ-PTT APTT 23.7 sec 22.1-36.1 SQ-PTT APTT 25.4 sec 22.1-36.1 SQ-PTT APTT 24.7 sec 22.1-36.1 SQ-PTT Superstat APTT 31.3 sec 22.1-36.1 SQ-PTT APTT 40.0 H sec 22.1-36.1 SQ-PTT APTT 45.0 H sec 22.1-36.1 SQ-PTT APTT 45.0 H sec 22.1-36.1 SQ-PTT APTT 33.6 sec 22.1-36.1 SQ-YPTT Superstat APTT 52.2 *** Note: New in H sec 22.1-36.1 SQ-YPT Superstat APTT 37.9 H sec 22.1-36.1		SQ-PTT	APTT	43.1	MODERATELY	Н	sec	22.1-35.1
SQ-PTT APTT 25.4 sec 22.1-36.1 SQ-PTT APTT 24.0 sec 22.1-36.1 SQ-PTT APTT 24.0 sec 22.1-36.1 SQ-PTT APTT 24.0 sec 22.1-36.1 SQ-PTT APTT 24.7 sec 22.1-36.1 SQ-PTT APTT 24.7 sec 22.1-36.1 SQ-PTT APTT 31.3 sec 22.1-36.1 SQ-PTT APTT 34.5 sec 22.1-36.1 SQ-PTT APTT 45.0 H sec 22.1-36.1 SQ-PTT APTT 45.0 H sec 22.1-36.1 SQ-PTT APTT 33.6 New n H sec 22.1-36.1 SQ-PTT APTT 37.9 H sec 22.1-36.1 SQ-PT SQ-PTT APTT 37.4 H sec 22.1-34.1 SQ-PT SQ-PTT APTT 37.2 SLT HEMOLYS H sec </th <th></th> <th>SQ-PTT</th> <th>APTT</th> <th>25.7</th> <th></th> <th></th> <th>sec</th> <th>22.1-35.1</th>		SQ-PTT	APTT	25.7			sec	22.1-35.1
SQ-PTT APTT 24.7 sec 22.1.36.1 SQ-PTT APTT 31.3 sec 22.1.36.1 SQ-PTT APTT 34.5 sec 22.1.36.1 SQ-PTT APTT 40.0 H sec 22.1.36.1 SQ-PTT APTT 45.0 H sec 22.1.36.1 SQ-PTT APTT 45.0 H sec 22.1.35.1 SQ-PTT Superstat APTT 52.0 "* Note: New n H sec 22.1.35.1 SQ-PTT Apertat APTT 34.3 sec 22.1.35.1 Sec SQ-PTT APTT 37.9 H sec 22.1.35.1 SQ-PTT APTT 37.4 H sec 22.1.34.1 SQ-PTT APTT 37.2 SLTHEMOLYS H <th></th> <th>SQ-PTT</th> <th>APTT</th> <th>23.7</th> <th></th> <th></th> <th>sec</th> <th>22.1-35.1</th>		SQ-PTT	APTT	23.7			sec	22.1-35.1
SQ-PTT APTT 24.0 sec 22.1-36.1 SQ-PTT APTT 24.7 sec 22.1-36.1 SQ-PTT Superstat APTT 31.3 sec 22.1-36.1 SQ-PTT APTT 34.5 sec 22.1-36.1 SQ-PTT APTT 44.5 sec 22.1-36.1 SQ-PTT APTT 40.0 H sec 22.1-36.1 SQ-PTT APTT 45.0 H sec 22.1-36.1 SQ-PTT APTT 45.0 H sec 22.1-35.1 SQ-XPTT Superstat APTT 55.2 *** Note: New n H sec 22.1-35.1 SQ-XPTT Superstat APTT 31.3 sec 22.1-35.1 sec 22.1-35.1 SQ-XPTT Superstat APTT 37.9 H sec 22.1-36.1 SQ-PTT APTT 37.4 H sec 22.1-34.1 SQ-PTT APTT 37.4 H sec 22.1-34.1 SQ-PTT		SQ-PTT	APTT	25.4			sec	22.1-35.1
SO-PTT APTT 24.7 sec 22.1-36.1 SO-XPTT Superstat APTT 31.3 sec 22.1-36.1 SO-PTT APTT 34.5 sec 22.1-36.1 SO-PTT APTT 40.0 H sec 22.1-36.1 SO-PTT APTT 45.0 H sec 22.1-36.1 SO-PTT APTT 45.0 H sec 22.1-36.1 SO-PTT APTT 33.6 H sec 22.1-36.1 SO-PTT APTT 33.6 sec 22.1-36.1 SO-PTT APTT 37.9 H sec 22.1-36.1 SO-PTT APTT 37.9 H sec 22.1-36.1 SO-PTT APTT 37.4 H sec 22.1-34.1 SO-PTT APTT 37.4 H sec 22.1-34.1 SO-PTT APTT 35.1 H sec 22.1-34.1 SO-PTT APTT 36.4 MODERATE H H		SQ-PTT	APTT	24.7			sec	22.1-35.1
SQ-XPTT Superstat APTT 31.3 sec 22.1-36.1 SQ-XPTT APTT 34.5 sec 22.1-36.1 SQ-PTT APTT 34.5 sec 22.1-36.1 SQ-PTT APTT 40.0 H sec 22.1-36.1 SQ-PTT APTT 45.0 H sec 22.1-36.1 SQ-XPTT Superstat APTT 55.2 *** Note: New n H sec 22.1-36.1 SQ-XPTT APTT 33.6 sec 22.1-36.1 sec 22.1-36.1 SQ-XPTT APTT 33.6 sec 22.1-36.1 sec 22.1-36.1 SQ-YTT APTT 37.9 H sec 22.1-35.1 sec 22.1-35.1 SQ-PTT APTT 37.4 H sec 22.1-36.1 sec 22.1-36.1 SQ-PTT APTT 37.4 H sec 22.1-34.1 sec 22.1-34.1 sec 22.1-34.1 sec 22.1-34.1 sec 22.1-34.1 s		SQ-PTT	APTT	24.0			sec	22.1-35.1
SQ-PTT APTT 34.5 sec 22.1-36.1 SQ-PTT APTT 40.0 H sec 22.1-36.1 SQ-PTT APTT 40.0 H sec 22.1-36.1 SQ-PTT APTT 45.0 H sec 22.1-36.1 SQ-XPTT Superstat APTT 55.2 *** Note: New n H sec 22.1-36.1 SQ-XPTT Superstat APTT 33.6 sec 22.1-36.1 sec 22.1-35.1 SQ-XPTT Superstat APTT 34.3 sec 22.1-36.1 sec 22.1-36.1 SQ-XPTT APTT 37.9 H sec 22.1-36.1 SQ-PTT APTT 37.4 H sec 22.1-34.1 SQ-PTT APTT 37.4 H sec 22.1-34.1 SQ-PTT APTT 35.1 H sec 22.1-34.1 SQ-PTT APTT 36.4 MODERATE HEH sec 22.1-34.1 SQ-PTT APTT 36.4		SQ-PTT	APTT	24.7			sec	22.1-35.1
SO-PTT APTT 40.0 H sec 22.1-35.1 SO-PTT APTT 45.0 H sec 22.1-35.1 SO-PTT Superstat APTT 55.2 *** Note: New n H sec 22.1-35.1 SO-PTT APTT 33.6 sec 22.1-35.1 sec 22.1-35.1 SO-PTT APTT 33.6 sec 22.1-36.1 sec 22.1-35.1 SO-PTT APTT 37.9 H sec 22.1-36.1 sec 22.1-36.1 SO-PTT APTT 27.9 H sec 22.1-36.1 sec 22.1-36.1 SO-PTT APTT 37.4 H sec 22.1-34.1 sec 22.1-34.1 SO-PTT APTT 37.2 SLT HEMOLYS sec 22.1-34.1 sec 22.1-34.1 SO-PTT APTT 36.4 MODERATE HEH sec 22.1-34.1 sec 22.1-34.1 So-PTT APTT 36.4 MODERATE HEH sec 22		SQ-XPTT	Superstat APTT				sec	22.1-35.1
SQ-PTT APTT 45.0 H sec 22.1-35.1 SQ-XPTT Superstat APTT 55.2 *** Note: New n H sec 22.1-35.1 SQ-XPTT APTT 33.6 sec 22.1-36.1 sec 22.1-35.1 SQ-XPTT Superstat APTT 34.3 sec 22.1-35.1 sec 22.1-35.1 SQ-XPTT APTT 37.9 H sec 22.1-35.1 SQ-PTT APTT 22.6 sec 22.1-34.1 SQ-PTT APTT 37.4 H sec 22.1-34.1 SQ-PTT APTT 37.2 SLT HEMOLYS H sec 22.1-34.1 SQ-PTT APTT 35.1 H sec 22.1-34.1 SQ-PTT APTT 35.4 MODERATE HE H sec 22.1-34.1 Record: Image: Im		SQ-PTT	APTT	34.5			sec	22.1-35.1
SQ-XPTT Superstat APTT 55.2 *** Note: New n H sec 22.1-35.1 SQ-XPTT APTT 33.6 sec 22.1-35.1 sec 22.1-35.1 SQ-XPTT Superstat APTT 34.3 sec 22.1-35.1 sec 22.1-35.1 SQ-XPTT Superstat APTT 37.9 H sec 22.1-36.1 SQ-PTT APTT 37.4 H sec 22.1-34.1 SQ-PTT APTT 37.4 H sec 22.1-34.1 SQ-PTT APTT 37.2 SLT HEMOLYS H sec 22.1-34.1 SQ-PTT APTT 36.4 MODERATE HEH sec 22.1-34.1		SQ-PTT	APTT	40.0		н	sec	22.1-35.1
SQ-PTT APTT 33.6 sec 22.1.36.1 SQ-PTT Superstat APTT 34.3 sec 22.1.36.1 SQ-PTT Apperstat APTT 37.9 H sec 22.1.35.1 SQ-PTT APTT 22.6 sec 22.1.35.1 SQ-PTT APTT 22.6 sec 22.1.34.1 SQ-PTT APTT 37.4 H sec 22.1.34.1 SQ-PTT APTT 37.2 SLT HEMOLYS H sec 22.1.34.1 SQ-PTT APTT 35.1 H sec 22.1.34.1 SQ-PTT APTT 36.4 MODERATE HEH sec 22.1.34.1 Record: Image: I		SQ-PTT	APTT				sec	22.1-35.1
SQ-XPTT Superstat APTT 34.3 sec 22.1-35.1 SQ-PTT APTT 37.9 H sec 22.1-35.1 SQ-PTT APTT 37.9 H sec 22.1-35.1 SQ-PTT APTT 37.9 H sec 22.1-36.1 SQ-PTT APTT 37.4 H sec 22.1-34.1 SQ-PTT APTT 37.2 SLT HEMOLYS H sec 22.1-34.1 SQ-PTT APTT 35.1 H sec 22.1-34.1 SQ-PTT APTT 36.4 MODERATE HE H sec 22.1-34.1 Record: Image: I		SQ-XPTT	Superstat APTT		*** Note: New n	Н	sec	22.1-35.1
SQ-PTT APTT 37.9 H sec 22.1-36.1 SQ-PTT APTT 22.6 sec 22.1-34.1 SQ-PTT APTT 37.4 H sec 22.1-34.1 SQ-PTT APTT 37.4 H sec 22.1-34.1 SQ-PTT APTT 37.2 SLT HEMOLYS H sec 22.1-34.1 SQ-PTT APTT 35.1 H sec 22.1-34.1 SQ-PTT APTT 36.4 MODERATE HEH sec 22.1-34.1 Record: Image:		SQ-PTT	APTT	33.6			sec	22.1-35.1
SQ-PTT APTT 22.6 sec 22.1-34.1 SQ-PTT APTT 37.4 H sec 22.1-34.1 SQ-PTT APTT 37.4 H sec 22.1-34.1 SQ-PTT APTT 37.2 SLT HEMOLYS H sec 22.1-34.1 SQ-PTT APTT 35.1 H sec 22.1-34.1 SQ-PTT APTT 36.1 H sec 22.1-34.1 SQ-PTT APTT 36.4 MODERATE HE H sec 22.1-34.1 Record: Image: Image							sec	
SQ-PTT APTT 37.4 H sec 22.1-34.1 SQ-PTT APTT 37.2 SLT HEMOLYS H sec 22.1-34.1 SQ-PTT APTT 37.1 H sec 22.1-34.1 SQ-PTT APTT 35.1 H sec 22.1-34.1 SQ-PTT APTT 35.1 H sec 22.1-34.1 SQ-PTT APTT 36.4 MODERATE HEH sec 22.1-34.1 Record: I		SQ-PTT	APTT			н	sec	22.1-35.1
SQ-PTT APTT 37.2 SLT HEMOLYS H sec 22.1-34.1 SQ-PTT APTT 35.1 H sec 22.1-34.1 SQ-PTT APTT 36.4 MODERATE HEH sec 22.1-34.1 Record::::::::::::::::::::::::::::::::::::		SQ-PTT	APTT	22.6			sec	22.1-34.1
SQ-PTT APTT 35.1 H sec 22.1-34.1 SQ-PTT APTT 36.4 MODERATE HE H sec 22.1-34.1 Record: T T T T Sec 22.1-34.1		SQ-PTT	APTT	37.4		н	sec	22.1-34.1
SQ-PTT APTT 36.4 MODERATE HE H sec 22.1-34.1		SQ-PTT	APTT	37.2	SLT HEMOLYS	н	sec	22.1-34.1
		SQ-PTT	APTT	35.1		н	sec	22.1-34.1
Record: 1 1 1 108164 4		SQ-PTT	APTT	36.4	MODERATE HE		sec	
	Re	cord: I4 4	1	108164				P
Datasheet View	· · · · ·	tasheet View						

Files include Small Database

One year's usage of RPDR

- 4526 registered users, 1113 new in just 2019
- 834 teams/year gathering data for research studies
- 4472 detailed patient data sets returned to these teams in 2019, containing data of 24.7 million patient records.
- From a survey of 153 teams
 - Importance of the data received from the RPDR was evaluated in relation to the study it was supporting.
 - Calculated over 4 years (FY15-FY19) the total agreement amounts were \$2.27 Billion, making per year consumption critically dependent on RPDR \$244 Million.



Rapid investigation of QTc prolongation

FDA warning 2011 for Celexa

Safety Announcement: [8-24-2011] "should no longer be used at doses greater than 40 mg per day because it can cause abnormal changes in the electrical activity of the heart."


- But, did NOT include Lexapro (which is active ingredient of Celexa [s-enantiomer])
- Shown to be true with RPDRderived data set with >38,000 EKGs obtained within 14 – 90 day window after medication initiated

Adjusted model [†]							
	prolongatio	p-value					
Anti-depressant	n						
SSRI							
Citalopram (Celexa)	2.85	0.004					
Escitalopram (Lexapro)	3.80	< 0.001					
Fluoxetine (Prozac)	1.44	0.150					
Paroxetine (Paxil)	0.07	0.943					
Sertraline (Zoloft)	0.87	0.383					
Other anti-depressants							
Amitriptyline	4.10	< 0.001					
Bupropion	-2.15	0.032					
Duloxetine	0.60	0.547					
Mirtazapine	-1.46	0.145					
Nortriptyline	1.23	0.219					
Venlafaxine	1.15	0.251					
previously known prolonger							
Methadone	5.32	< 0.001					
† Adjusted for age, gender, race, type of insurance, history of major depression, history of myocardial infarction and Charlson comorbidity score							


Roy Perlis MD, MSc and team

Relevant Cohorts of Patients are Gathered through RPDR and Detailed Data Obtained

- Medication use by individual patients over time
- Patient EKG QTc values at various time points



Results: QTc interval and medication use



^{*} Dose a significant predictor of QTc in fully adjusted linear models at α =0.05

† QTc at specified dose is significantly different from that at prior dose in fully adjusted linear models at α=0.05

Mean (SD) corrected QT (QTc) interval recorded on electrocardiogram 14–90 days after prescription of antidepressant or methadone, by drug dose


High Throughput Methods for supporting Translational Research

- Set of patients is selected from medical record data in a high throughput fashion
- Investigators explore phenotypes of these patients using Machine Learning tools and a translational team developed to work specifically with medical record data
- Distributed networks cross institutional boundaries for phenotype selection, public health, and hypothesis testing
- Digital medicine is delivered into clinical care through Digital Twin

RPDR Evolved into international "Informatics for Integrating Biology and the Bedside (i2b2)" sponsored by the National Institutes of Health, what is it?

- Software for explicitly organizing and transforming personoriented clinical data to a way that is optimized for clinical genomics research
 - Allows integration of clinical data, trials data, and genotypic data
- A portable and extensible application framework
 - Software is built in a modular pattern that allows additions without disturbing core parts
 - Available as open source at <u>https://www.i2b2.org</u>


I2b2 Community Software distributed as open source




I2b2 Software adapts through new plugins

Contraction - i2b2 Wiki - Windows Internet Explorer	
🕢 💽 🗢 🔣 https://community.i2b2.org/wiki/dashboard.action 🛛 🔹 🔒 🍫 🗙 🚼 Googl	e 🔎 🔽
File Edit View Favorites Tools Help	
Favorites Dashboard - i2b2 Wiki	
 i2b2 Sponsored Project - i2b2 Web Client The i2b2 Web Client is one of several core projects that are directly sponsored by the i2b2 team. 	
Image: system of the image:	
Related Project - Clinical Trender @ The Clinical Trender aims to allow researchers to track and visualize certain clinical variables related to a selected p @	B)
Related Project - CRC Tester A Workbench plugin that tests the CRC web services by Mike Mendis A	E
Image: Related Project - Crimson Image: Related Project - Crimson A project to make specimens available through i2b2 infrastructure, organized by Lynn Bry	
Related Project - ExportXLS The i2b2 Web Client Plugin that tabulates patient data & applicable specified concepts; and facilitates export to spread	
Image: Related Project - FACE caGrid CQL2 Data Source Image: Related Project - FACE caGrid CQL2 Data Source A caGrid/TRIAD data service that runs i2b2 queries via the RESTful interface to CRC Image: Related Project - FACE caGrid CQL2 Data Source	
 Related Project - Familial, Associational, & Incidental Relationships (FAIR) Initiative. A collection of DBA tools and webclient plugins to facilitate the identification of related concepts amongst related pat 	
 Related Project - Federated Query Simulations Simulations of federated query tools that return aggregate counts, such as SHRINE, by Griffin Weber 	-
See Internet Protected Mode: C	off 🛛 🖓 👻 🔍 100% 👻 🚲

Genotype Data






https://community.i2b2.org/wiki/display/IGD/Loading+Genomic+VCF+Files+into+i2b2


Use NLP to extract the relevant features from the set of patient notes.



LMM Enhanced interaction with Patient Representation




Medical conditions supported by description in chart



Emily Alsentzer et al


Zero-shot Interpretable Phenotyping of Postpartum Hemorrhage Using Large Language Models medRxiv preprint doi: https://doi.org/10.1101/2023.05.31.23290753

Data Integration in Big Data Commons




Curating a Disease Algorithm


1. Create a gold standard training set.




2. Create a comprehensive list of features from patient's electronic data that describe the disease of interest



3. Develop the classification algorithm. Using the data analysis file and the training set from step 1, assess the frequency of each variable. Remove variables with low prevalence. Apply adaptive LASSO penalized logistic regression to identify highly predictive variables for the algorithm



4. Apply the algorithm to all subjects in the superset and assign each subject a probability of having the phenotype




Biobank Portal | Curated Diseases

Validated Phenotype	Count*	Predictive Positive Value
Bipolar Disease	71	89%
Congestive Heart Failure	387	90%
Coronary Artery Disease	2,420	97%
Crohn's Disease	453	90%
Multiple Sclerosis	94	90%
Rheumatoid Arthritis	550	90%
Type 2 Diabetes Mellitus	1,887	97%
Ulcerative Colitis	330	90%

Healthy Controls based on Charlson Index	Count**
0 – 10-year survival probability is >98.3%	2,206
1 – 10-year survival probability is >95.87%	4,343
2 – 10-year survival probability is >90.15%	6,545

* Based on 15,880 patients ** Based on 21,300 patients

Automated Learning Algorithms enabled in RPDR such as PheNorm Algorithm



J Am Med Inform Assoc. 2018 Jan 1;25(1):54-60. doi: 10.1093/jamia/ocx111.

Enabling phenotypic big data with PheNorm.

Machine Learned Phenotypes

- Abdominal hernia
- Acute bronchitis and bronchiolitis
- Acute pancreatitis ٠
- Alcoholism ٠
- Alzheimer's disease .
- Aortic aneurysm ٠
- Aplastic anemia
- Atrial fibrillation
- Atrioventricular block
- Autism spectrum disorders
- Basal cell carcinoma
- **Bipolar** Disease
- Bladder cancer
- Brain cancer .
- Breast cancer ٠
- Cerebral aneurysm ٠
- Cholelithiasis ٠
- Chronic pancreatitis ٠
- Chronic sinusitis ٠
- Coronary atherosclerosis ٠
- Crohn's disease ٠
- Deep vein thrombosis ٠
- Depression
- Diverticulosis and diverticulitis
- Eating disorder
- Epilepsy
- Gastroesophageal reflux disease
- Gout
- Heart valve disorders

- Hyperlipidemia
- Hyperparathyroidism
- Hypertension
- Hypothyroidism •
- Insomnia •
- Intracranial hemorrhage .
- Ischemic stroke .
- Leukemia
- Lung cancer
- Melanoma
- Migraine headache .
- Multiple sclerosis
- Myocardial infarction •
- Neutropenia ٠
- Non-Hodgkin lymphoma
- Obesity ٠
- Obsessive compulsive disorder .
- Obstructive sleep apnea •

- Parkinson's disease
- Peripheral vascular disease
- Pneumonia
- Polycystic ovaries
- Pulmonary heart disease
- Renal cancer .
- Renal failure .
- Schizophrenia
- Substance addiction

- Suicidal ideation
- Suicide attempt or self-inflicted injury
- Thyroid cancer ٠
- Tobacco use disorder ٠
- Type 1 diabetes
- Type 2 diabetes
- Ulcerative colitis
- Urinary calculus ٠
- Uterine cancer

- Ovarian cancer
- Pancreatic cancer
- ٠

- Prostate cancer


Phenotype Automation: Phenotype Quality Dashboard

category PheWAS_code abbr PheWAS_name model ICD_PPV ICD_AUC AUC PPV TPR ONC PheWAS:189.21 BLCA Bladder cancer PheNorm_ICD 0.80 0.003 1.000 1.00 0.42 ONC PheWAS:204 LEUK Leukemia PheNorm_ICD 0.73 1.000 1.00 0.01 PSYCH PheWAS:297.1 SI Suicidal ideation PheNorm_ICDNLP 0.93 0.482 1.000 1.00 0.43 PSYCH PheWAS:305.2 EATD Eating disorder PheNorm_ICDNLP 0.93 0.482 1.000 1.00 0.50 NEURO PheWAS:327.4 INSOM Insomnia PheNorm_ICDNLP 0.87 0.682 1.00 1.00 0.50 NEURO PheWAS:452.2 DVT Deep vein thrombosis PheNorm_ICDNLP 0.87 0.682 1.00						Phe	notypes M	ethods	About us		
ONC PheWAS:204 LEUK Leukemia PheNorm_ICD 0.73 1.000 1.000 0.01 PSYCH PheWAS:297.1 SI Suicidal ideation PheNorm_ICDNLP 0.93 0.786 1.000 1.000 0.43 PSYCH PheWAS:305.2 EATD Eating disorder PheNorm_ICDNLP 0.93 0.482 1.000 1.000 1.000 NEURO PheWAS:327.4 INSOM Insomnia PheNorm_ICDNLP 0.93 0.821 1.000 1.000 0.50 NEURO PheWAS:452.2 DVT Deep vein thrombosis PheNorm_ICDNLP 0.87 0.692 1.000 1.00 1.00 NEURO PheWAS:452.2 DVT Deep vein thrombosis PheNorm_ICDNLP 0.87 0.692 1.00 1.00 1.00 NEURO PheWAS:817 CONC Concussion PheNorm_ICDNLP 0.73 0.682 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00	category 🔶	PheWAS_code 🔶	abbr 🕴	PheWAS_name 🝦	model 🔶	ICD_PPV 🔶	ICD_AUC 🔶	AUC 🔶	PPV 🔶	TPR 🔶	
PSYCH PheWAS:297.1 SI Suicidal ideation PheNorm_ICDNLP 0.93 0.786 1.000 1.00 0.43 PSYCH PheWAS:305.2 EATD Eating disorder PheNorm_ICDNLP 0.53 0.482 1.000 1.00 1.00 NEURO PheWAS:327.4 INSOM Insomnia PheNorm_ICDNLP 0.93 0.821 1.000 1.00 0.50 CARDIO PheWAS:452.2 DVT Deep vein thrombosis PheNorm_ICDNLP 0.87 0.692 1.00 1.00 1.00 NEURO PheWAS:452.2 DVT Deep vein thrombosis PheNorm_ICDNLP 0.87 0.692 1.00 1.00 1.00 NEURO PheWAS:452.2 DVT Concussion PheNorm_ICDNLP 0.73 0.682 1.00 1.00 1.00 METAB PheWAS:250.1 T1DM Type 1 diabetes PheNorm_ICDNLP 0.60 0.926 0.91 Artici aneurysm (AA) Throw phewas:184.11 OVCA Ovarian cancer PheNorm_ICDNLP 0.60 0.926 0.91 Phenotypes Artici aneurysm (AA)	ONC	PheWAS:189.21	BLCA	Bladder cancer	PheNorm_ICD	0.80	0.903	1.000	1.00	0.42	
PSYCH PheWAS:305.2 EATD Eating disorder PheNorm_ICDNLP 0.53 0.482 1.000 1.00 1.00 NEURO PheWAS:327.4 INSOM Insomnia PheNorm_ICDNLP 0.93 0.821 1.000 1.00 0.50 CARDIO PheWAS:452.2 DVT Deep vein thrombosis PheNorm_ICDNLP 0.87 0.692 1.00 1.00 1.00 NEURO PheWAS:817 CONC Concussion PheNorm_ICDNLP 0.73 0.682 1.00 1.00 1.00 METAB PheWAS:250.1 T1DM Type 1 diabetes PheNorm_ICDNLP 0.60 0.926 0.91	ONC	PheWAS:204	LEUK	Leukemia	PheNorm_ICD	0.73	1.000	1.000	1.00	0.91	
NEURO PheWAS:327.4 INSOM Insomnia PheNorm_ICDNLP 0.93 0.821 1.00 1.00 0.50 CARDIO PheWAS:452.2 DVT Deep vein thrombosis PheNorm_ICDNLP 0.87 0.692 1.00 1.00 1.00 NEURO PheWAS:817 CONC Concussion PheNorm_ICDNLP 0.73 0.682 1.00 1.00 1.00 METAB PheWAS:250.1 T1DM Type 1 diabetes PheNorm_ICDNLP 0.60 0.926 0.91 Image: Cardiology ONC PheWAS:184.11 OVCA Ovarian cancer PheNorm_ICDNLP 0.60 0.926 0.91 Image: Cardiology	PSYCH	PheWAS:297.1	SI	Suicidal ideation	PheNorm_ICDNLP	0.93	0.786	1.000	1.00	0.43	
CARDIO PheWAS:452.2 DVT Deep vein thrombosis PheNorm_ICDNLP 0.87 0.692 1.00 1.00 1.00 1.00 NEURO PheWAS:817 CONC Concussion PheNorm_NLP 0.73 0.682 1.00 <td< td=""><td>PSYCH</td><td>PheWAS:305.2</td><td>EATD</td><td>Eating disorder</td><td>PheNorm_ICDNLP</td><td>0.53</td><td>0.482</td><td>1.000</td><td>1.00</td><td>1.00</td><td></td></td<>	PSYCH	PheWAS:305.2	EATD	Eating disorder	PheNorm_ICDNLP	0.53	0.482	1.000	1.00	1.00	
CARDIO PheWAS:452.2 DVT thrombosis PheNorm_ICDNLP 0.87 0.692 1.00 1.00 1.00 NEURO PheWAS:817 CONC Concussion PheNorm_NLP 0.73 0.682 1.00 1.00 1.00 1.00 METAB PheWAS:250.1 T1DM Type 1 diabetes PheNorm_ICD 0.17 0.882 0.94 Image: Cardiology ONC PheWAS:184.11 OVCA Ovarian cancer PheNorm_ICDNLP 0.60 0.926 0.94 Image: Cardiology	NEURO	PheWAS:327.4	INSOM	Insomnia	PheNorm_ICDNLP	0.93	0.821	1.000	1.00	0.50	
NEURO PheWAS:817 CONC Concussion PheNorm_NLP 0.73 0.682 1.01 METAB PheWAS:250.1 T1DM Type 1 diabetes PheNorm_ICD 0.17 0.882 0.91 ONC PheWAS:184.11 OVCA Ovarian cancer PheNorm_ICDNLP 0.60 0.926 0.91	CARDIO	PheWAS:452.2	DVT		PheNorm_ICDNLP	0.87	0.692	1.000			
ONC PheWAS:184.11 OVCA Ovarian cancer PheNorm_ICDNLP 0.60 0.926 0.91	NEURO	PheWAS:817	CONC	Concussion	PheNorm_NLP	0.73	0.682	1.00		_	
ONC PheWAS:184.11 OVCA Ovarian cancer PheNorm_ICDNLP 0.60 0.926 0.94	METAB	PheWAS:250.1	T1DM	<u>Type 1 diabetes</u>	PheNorm_ICD	0.17	0.882	0.9			
🗇 🔂 Caranzar, athereoderacia (/	ONC	PheWAS:184.11	OVCA	Ovarian cancer	PheNorm_ICDNLP	0.60	0.926	0.9			
0 ONC PheWAS:182 UTCA Uterine cancer PheNorm_ICD 0.50 0.867 0.91	ONC	PheWAS:182	UTCA	Uterine cancer	PheNorm_ICD	0.50	0.867	0.9			vein thrombosis (CAD)
1 GI PheWAS:555.1 CD <u>Crohn's disease</u> PheNorm_mean 0.54 0.961 0.9i 	GI	PheWAS:555.1	CD	Crohn's disease	PheNorm_mean	0.54	0.961	0.9		🗄 🫅 Heart	valve disorders (HVD)

High Quality Phenotypes for Research Studies

<u>File Edit V</u> iew Hi <u>s</u> tory <u>B</u> ookmarks <u>T</u> ools <u>H</u> elp		_					_ 0	x
Partners Biobank Portal × +								
Employed Antropy A-0/?user=snm0	C	Q Search	+		1 🖻 🛡	1 🐖	-	≡
PARTNERS BIOBANK PORTAL Biobank Portal Genomic Pilot [Logout]		🚨 Find Patients	S Make Reques	at 🔛 H	elp & Support	Shawr	n Murphy, M	ID
Navigate Terms Find Biobank Consent Information () Biobank Consent Information () Biobank Demographics () Biobank Genomics () All people with genomic data - 9358 Carbon dbSNP rs Identifier - 4930 () Biobank Health Information Survey () Biobank Sample Types () Curated Disease Populations () Asthma (AST) () Bioplar Disorder (BD) () Bioplar Disorder (BRCA) ()	Query Tool Query Name: Prima-CHFGen Temporal Constraint: Group 1 Dates Occurs > 0x Treat Independently ▼ Primary dilated cardiomy 4002	X Exclude Dates	Treat all group Group 2 Occurs > 0x Independently * F - current or past hist 700	Exclude	Dates Treat Indepe Concerning Homozygous missense O	✓ Group 3 Occurs > 0x andently ✓ Intains "TTN ANI s AND (Framesl R nonsense OF R stop_loss)"] One or	Exclude D Dift OR	
Corporative Heart Failure (CHF) Congestive Heart Failure (CHF) Congestive Heart Failure (CHF) CHF - current or past history (PPV 0.90) - 700 CHF - no history (NPV 0.99) - 36024 Coronary Artery Disease (CAD)	Run Query Clear		more of these			more of these		
			·					<u> </u>
⊕ 🔂 Epilepsy (EPIL) 🕦	Show Query Status Gra	aph Results Que	ery Report Downl	oad Results	S		Ę	1
 Gout (GOUT) 1 Hypertension (HTN) 1 Multiple Sclerosis (MS) 1 Obesity (OBES) 1 Rheumatoid Arthritis (RA) 1 			Number of patients	5				
Schizophrenia (SCZ) (1) Type 1 Diabetes Mellitus (T1DM) (1) Type 2 Diabetes Mellitus (T2DM) (1) Type 2 Diabetes (1) Type 2 D		For Query "	"Prima-CHFGene(@14:22:40)"		-	-


Combined with Generative AI can produce _ Digital Twin of Patient




High Throughput Methods for supporting Translational Research

- Set of patients is selected from medical record data in a high throughput fashion
- Investigators explore phenotypes of these patients using Machine Learning tools and a translational team developed to work specifically with medical record data
- Distributed networks cross institutional boundaries for phenotype selection, public health, and hypothesis testing
- Digital medicine is delivered into clinical care through Digital Twin

I2b2 Implementations >250 across the USA and Internationally, some illustrated below:



Federated Queries



Drive Pragmatic Clinical Studies

🗅 i2b2 Web Client 🛛 🗙 🔽			_			-	L	- 0 <mark>-</mark> ×		-												<u> </u>				
→ C 🛈 Not secure i2b2act.dipr.partners.org/AC	TFullDemo/	#						ፃ 🏠 🚺 (O I	s.org/ACTFull	Demo/#												키 ☆			
b2 Ouery & Analysis Tool Project ACT Develop	nentUser: Cr	oniob Sei	vice Find Pat	ients A	Analysis Tools	I Message Log Heli	p Change Pa	ssword Logo	ut :1	F Development l	Jser: Cro	niob Se	ervice Fi	nd Patie	ents I A	nalvsis	Tools	🚽 I Me	ssage Lo	oa I He	lp Ch	nange Pa	asswor	rd Loc		
Navigate Terms Find 💦 🕏 🔍	Patient Se	Patient Set Viewer					ð 🕑 🕠		- Patient Data A	nalysis		_	8 °C										Giliph 🌐 Table			
E Cardiovascular agents	Specify D	ata Vi	ew Patients																							
🖻 🔂 Central nervous system agents										Vitals			_	Me 🗹	dications				_	🖊 Labs						
⊕- C Analgesics		11016	4 F	65	WHITE		Yes	Nc		Weight, Blood Pres	sure		•	Me	toprolol, Spi	ironolactor	ne, Valsarta	an 🔻		Creatini	ne, Potass	ium, eGFR		•		
Anorexiants Anticonvulsants							100																			
Antiemetic antivertigo agents		12310	14 F	63	WHITE		Yes	NC																		
		12319	2 M	64	WHITE		Yes	Nc						Viewinį	g 2 weeks st	tarting from	n 01/0	07/17 🗎								
🕀 🔂 General anesthetics		12010	12 111	04			163	THE .					ER Visit	s —	ICU Visits	Fic	oor Visits	CI	inic Visits	_						
🕀 🔂 Miscellaneous central nervous system		12441	5 M	62	HISPANIC		Yes	Nc					14		2	5	6	3	3							
agents 🗸		12667	'3 F	76	WHITE		Yes	Nc			01/07/17	01/08/17	01/09/17	01/10/17	01/11/17	01/12/17	01/13/17	01/14/17	01/15/17	01/16/17	01/17/17	01/18/17	01/19/17	01/20/1		
orkplace 🔂 🖏		13070	12 M	81	WHITE		Yes	Nc		Events					ICD											
Cronjob		13077	'3 M	80	UNKNOWN	[Sinemet 25/100 - LMR 691](15)	Yes	Nc		View.All		Echo			Implant											
		13992	6 M	68	WHITE	[Sinemet 25/100 - LMR 691](5)	Yes	Nc		Weight (Ibs) View All	200	202	230	150	400	430	500	506	100							
- § 160803 - § 24339		15143	0 M	62	WHITE		Yes	Nc		Blood Pressure																
- 60677 - 91326		15849	2 F	78	WHITE		Yes	N		(mmHg) View All																
evious Queries Find Q 🗘 🖓 🖓	V	16080	13 F	63	WHITE	[Sinemet 25/100 - LMR 691](2) [Pramipexole (mirapex) - LMR 2639](2)	Yes			Metoprolol (mg) View All Spironolactone				25	25	25	25	50	50	50	50	50	50	50		
Parkins-Tobacco@12:12:29 [4-12-2017] [cronjob]		16612	9 M	62	WHITE	[Sinemet 25/100 cr - LMR 1069](8)	Yes	N	1	: (mg) <u>View All</u>	50	50	50													
- Parkins-Tobacco@12:10:33 [4-12-2017] [cronjob]		17179	4 M	62	WHITE		Yes	Nc		Valsartan (mg)																
Fetus or newbor@12:14:33 [4-11-2017] [cronjob]						[Sinemet 25/100 -				View All																
Parkins-Tobacco@11:59:18 [4-11-2017] [cronjob]		17776	i2 M	74	WHITE	[Sinemet 25/100 -	Yes	Nc																		
Parkins-Tohacco@11:58:24 [4-11-2017] [cronioh]								•		Creatinine																

RECOVER Study Data Harmonization



RECOVER: Researching COVID to Enhance Recovery

The National Institutes of Health (NIH) created the RECOVER Initiative to learn about the long-term effects of COVID.

The goal of RECOVER is to rapidly improve our understanding of and ability to predict, treat, and prevent PASC (post-acute sequelae of SARS-CoV-2), including Long COVID.


LEARN MORE ABOUT LONG COVID (






https://recovercovid.org

Data harmonized within i2b2 star schema



Concepts in database available in harmonized ontology



New i2b2 Query Tool to be released:

i2b2 Query & Analysis Tool		simmons university	?	٢
Queries #	Find Patients Analysis Tools			0
Q Any Category -	Find Patients O with O without • when	C)	Í
 	 Endocrine, nutritional and metabolic diseases (e00-e89) or drag additional concepts Set date range this entire panel The start of the first occurrence of Event 1 occurs before the start of the first occurrence of Event 2 Event 2 Pormones or drag additional concepts 			
		Find Patients Cle	ear Al	
Hind derinentation 10:53:51 [9-22-2023] [demo]	Finished Query: (t) Query 4- Female-Age Temporal - Endocrine Hormones Compute Time: 0.4 secs Number of patients 6	[0.5 secs] View R	teport	

https://i2b2transmart.org/2023-i2b2-symposium/2023-symposium-recordings-slides/

I2B2 AI


User asks a question

i2b2 Query & Analysis Tool

? (2)

I want to find all patients with a diagnosis of acute respiratory

Result rendered in web client



Al returns response in i2b2 format

I want to find all patients with a diagnosis of acute respiratory infections who have also been prescribed bronchodilators.

<query_definition>

<query_name>Acute respiratory i@19:45:36</query_name>

<query_timing>ANY</query_timing>

<specificity_scale>0</specificity_scale>

<panel>

<panel_number>1</panel_number>

<panel_timing>ANY</panel_timing>

<panel_accuracy_scale>100</panel_accuracy_scale>

<invert>0</invert>

<total_item_occurrences>1</total_item_occurrences>

```
<item>
```

<hlevel>3</hlevel>

<item_name>Acute respiratory infections</item_name>

<item_key>\\iSyph\Diagnoses\Respiratory system (460-519)\Acute respiratory infections (460-466)\</item_key>

<item_icon>FA</item_icon>

<tooltip>Diagnoses \ Respiratory system \ Acute respiratory infections</tooltip>

<class>ENC</class>

<constrain_by_date>

<date_from/>


</constrain_by_date>

<item_is_synonym>false</item_is_synonym>

</item>

</panel>


AI-ENABLED QUERY BUILDER: (I.E. INSTRUCTION-TUNED POC)



High Throughput Methods for supporting Translational Research

- Set of patients is selected from medical record data in a high throughput fashion
- Investigators explore phenotypes of these patients using Machine Learning tools and a translational team developed to work specifically with medical record data
- Distributed networks cross institutional boundaries for phenotype selection, public health, and hypothesis testing
- Digital medicine is delivered into clinical care through Digital Twin

Congestive Heart Failure



Affects 2% of the adult population

Risk of death first year after diagnosis: 35%

 In patient hospital costs in 2011: \$10.5B which is a small fraction of all heart failure related care

Early Detection of Worsening or Improving Anemia

Background and Methods


- Anemia is one of the strongest predictors of morbidity and mortality in CHF.
- Increasing or decreasing HGB is a further strong predictor, but there is no good way to determine whether a patient's HGB is on its way up or down (*Circulation. 2005;112:1121-1127*)

Results and Conclusions


 A novel mathematical model of the RBC lifecycle enables estimation of patient-specific rates of RBC maturation and turnover from a routine CBC.

Applications


- 1. CHF patients most likely to have decreasing HGB may benefit from altered treatment or longer hospitalization to avoid readmission.
- 2. CHF patients most likely to have increasing HGB may be responding well to treatment and benefit from earlier discharge or maintenance of current therapy.



Quantify Maturation and Clearance Rates




Creatinine Prediction: Hypothetical Application




•Hypothetical analysis of creatinine times series where possible treatments are introduced into the model


•The model hypothetically provide a future trajectory conditioned on each treatment



Bringing Big Data into Clinical Care with Open App Development




Transforming Care in the Digital Age



Continuous Process Improvement

Convenience for Patient Communication

MGB Data Enclave Overview







I2b2 tranSMART Software

i2b2 Homepage (<u>https://www.i2b2.org</u>) i2b2 Software (<u>https://www.i2b2.org/software</u>) i2b2 Community Site (<u>https://community.i2b2.org</u>) https://i2b2transmart.org/2023-i2b2-symposium/2023symposium-recordings-slides/